Article
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Clinical drug investigation - 1 Apr 2018
Mann Helen, Andersohn Frank, Bodnar Carolyn, Mitsudomi Tetsuya, Mok Tony S K, Yang James Chih-Hsin, Hoyle Christopher
Abstract excerpt
BACKGROUND AND OBJECTIVE: An adjusted indirect comparison was conducted to assess efficacy outcomes, particularly overall survival (OS), of osimertinib versus platinum-based doublet chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) T790M mutation-positive non-small-cell lung cancer (NSCLC) who had progressed following an EGFR tyrosine kinase inhibitor (TKI). Analysis of treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.